Drawing for BOEHRINGER INGELHEIM BIOXCELLENCE

USPTO serial 79127685

BOEHRINGER INGELHEIM BIOXCELLENCE

Reviewed by CopyMark Law Group

Reg. 4634652Status 739Registered
Filing date
Status date
Registration date
Nov 11, 2014
Examiner
DALIER, JOHN DAVID
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with BOEHRINGER INGELHEIM BIOXCELLENCE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Max Moskowitz

Max Moskowitz Ostrolenk Faber LLP845 THIRD AVENUE, 17th FloorNew York, NY 10022United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biological products, substances and preparations for industrial and scientific purposes as well as for research purposesACTIVE—
005pharmaceutical preparations for the treatment of diseases and disorders of the alimentary tract and metabolism, and blood and blood forming organs; pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; and pharmaceutical preparations for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; preparations for destroying vermin; fungicides, herbicides; bacteriological cultures for medical and veterinary purposes as well as culture media for bacteriological cultures; bacteriological preparations for medical and veterinary use for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system and for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; biological preparations for medical and for veterinary purposes for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system and for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; biochemical preparations for medical and veterinary purposes for the treatment of diseases and disorders of the alimentary tract and metabolism, blood and blood forming organs, cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system and for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely, for diseases and disorders of the alimentary tract and metabolism, and blood and blood forming organs; pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; and pharmaceutical preparations for the treatment of dermatological, hormonal, infectious, viral and oncological diseases and disorders; ferments for pharmaceutical purposes; vaccines; culture media for microorganisms; plasters and dressings for medical purposesACTIVE—
016Printed matter, namely, newspapers, photographs, magazines, books, printed periodicals, newsletters, and brochures all in the field of pharmaceutical preparations; paper; cardboard; goods made from paper and cardboard, namely, boxes of paper and cardboard boxes; cardboard packaging, namely, pharmaceutical packaging; patient record cards and prescription pads; in the field of in the fields of medicine and pharmaceuticals; printed teaching and instructional materials, namely, pharmaceutical information leaflets;books in the fields of medicine and pharmaceuticals; printed publications, namely, magazines, newsletters,pamphlets, reports, instructional and information leaflets, and posters in the fields of medicine and pharmaceuticals; paper packaging, namely, packaging containers of paper; stationery; printed instructional and teaching materials relating to the pharmaceutical, health care and medical fields, in the field of research, medicine, veterinary and laboratory techniquesACTIVE—
035Compilation of data in computer databases, in particular in the field of biotechnology and biopharmaceutics; management in connection with the commercialization of technical or scientific results; management relating to the organisation of research; creation, namely, writing and compiling of manufacturing and registration dossiers for pharmaceutical products for third parties; office work, namely, operation of registration proceedings for pharmaceutical productsACTIVE—
038[ Transmitting medical and scientific information by means of a database]SECTION 71 - CANCELLED—
040Custom manufacture of pharmaceuticals, pharmaceutical ingredients, chemical products and chemical intermediates as well as of biological and biochemical products for third parties; treatment of biological materials, namely, batch treatment services with respect to microorganisms and proteinsACTIVE—
042Scientific and technological services, namely, scientific research, analysis and testing of active substances, medicine and treatment in the field of biotechnology; research and development of new products for other sand scientific laboratory services in the field of biotechnology; performance of chemical, biochemical and biological analysis; development of biological, biotechnological and pharmaceutical analysis and their application for others; technical and scientific consultancy, particularly in the field of biotechnology; scientific research; conducting clinical trials for others of pharmaceutical products; providing scientific information via the Internet in the field of pharmaceutical, health care and medical fields; scientific research consulting in the field of pharmaceutical, health care and medical fieldsACTIVE—
044Medical and veterinary consulting; providing medical and veterinary information via the Internet; all the aforementioned consultations and services also provided through a database; providing medical information via the InternetACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 25, 2026INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Dec 7, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 7, 2025NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Apr 7, 2025C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Apr 7, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 5, 2024ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 7, 2024INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jul 16, 2024XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jul 16, 2024XXCRGENERIC MADRID TRANSACTION CREATED—
Jun 14, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Nov 11, 2023REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Sep 29, 2023NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Sep 29, 202371.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
May 18, 2023EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Nov 26, 2022PR71POST REGISTRATION ACTION MAILED - SEC.71—
Nov 18, 2022EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Nov 17, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 17, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Nov 17, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Nov 17, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 17, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 29, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
May 18, 2022PR71POST REGISTRATION ACTION MAILED - SEC.71—
Jan 21, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 12, 2020ES71TEAS SECTION 71 RECEIVED—
Nov 11, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Apr 24, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 3, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 3, 2015FIMPFINAL DISPOSITION PROCESSED—
Feb 11, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 11, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 2, 2014OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Sep 17, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 17, 2014OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Aug 26, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 26, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 22, 2014GPNXNOTIFICATION PROCESSED BY IB—
Aug 6, 2014OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 6, 2014OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 6, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 23, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 23, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 22, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 22, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 22, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 23, 2014GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 23, 2014GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 23, 2014CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 21, 2014ZZAXPREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU—
Jan 20, 2014PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jan 7, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 7, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 7, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Jan 7, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 7, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 7, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 6, 2014ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Dec 21, 2013PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Dec 6, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 5, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 20, 2013ACECAMENDMENT FROM APPLICANT ENTERED—
Nov 20, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 12, 2013ALIEASSIGNED TO LIE—
Nov 1, 2013ALIEASSIGNED TO LIE—
Oct 31, 2013MAILPAPER RECEIVED—
Oct 25, 2013TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 19, 2013RFNTREFUSAL PROCESSED BY IB—
Apr 26, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 26, 2013RFRRREFUSAL PROCESSED BY MPU—
Apr 26, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 25, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2013RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Apr 20, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 19, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 19, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 15, 2013DOCKASSIGNED TO EXAMINER—
Apr 15, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 11, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance